

Cyrus Khandanpour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9410170/publications.pdf>

Version: 2024-02-01

86
papers

1,513
citations

430442

18
h-index

344852

36
g-index

89
all docs

89
docs citations

89
times ranked

2589
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. <i>British Journal of Haematology</i> , 2022, 196, 995-1006.	1.2	10
2	Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2022, 14, 565.	1.7	3
3	High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in MLL/AF9 Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 486.	1.7	11
4	A synthetic covalent ligand of the C/EBP β transactivation domain inhibits acute myeloid leukemia cells. <i>Cancer Letters</i> , 2022, 530, 170-180.	3.2	8
5	Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. <i>Cancers</i> , 2022, 14, 43.	1.7	9
6	Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 826342.	1.3	3
7	Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS). <i>International Journal of Molecular Sciences</i> , 2022, 23, 411.	1.8	2
8	GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 2196-2207.	3.3	7
9	Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1930-1939.	0.6	1
10	Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSM. <i>Cancers</i> , 2021, 13, 1322.	1.7	6
11	The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. <i>Nature Immunology</i> , 2021, 22, 769-780.	7.0	107
12	Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 757664.	1.3	3
13	Leukaemia Cells Induced Metabolic Alterations in AML Associated Mesenchymal Stem Cells Via Notch Signalling. <i>Blood</i> , 2021, 138, 4347-4347.	0.6	0
14	Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3365-3365.	0.6	0
15	Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial. <i>Blood</i> , 2021, 138, 463-463.	0.6	19
16	Targeting PI3K-AKT-mTOR Signaling in Multiple Myeloma Mesenchymal Stem Cells Mediates Antiproliferative Effect on Myeloma Cells. <i>Blood</i> , 2021, 138, 1600-1600.	0.6	0
17	Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1907-1915.	0.8	4
18	Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial. <i>Blood</i> , 2020, 136, 44-45.	0.6	16

#	ARTICLE	IF	CITATIONS
19	Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
20	AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone. <i>Blood</i> , 2020, 136, 1-1.	0.6	0
21	Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice. <i>Leukemia</i> , 2019, 33, 110-121.	3.3	16
22	CURCUMIN AS A NOVEL EPIGENETIC TREATMENT APPROACH FOR GFI1-ASSOCIATED MDS/AML. <i>Experimental Hematology</i> , 2019, 76, S85.	0.2	0
23	Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 824.	1.3	21
24	Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 839.	1.3	6
25	LSD1 inhibition by tranlycypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. <i>Leukemia</i> , 2019, 33, 1411-1426.	3.3	53
26	PF215 THE ROLE OF GROWTH FACTOR INDEPENDENCE 1 (GFI1) IN GENOME STABILITY, DNA REPAIR AND LEUKEMIA GENOMIC EVOLUTION. <i>HemaSphere</i> , 2019, 3, 59.	1.2	0
27	GFI1 is required for RUNX1/ETO positive acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e395-e399.	1.7	13
28	GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. <i>Nature Communications</i> , 2018, 9, 1418.	5.8	42
29	Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2018, 103, 614-625.	1.7	21
30	Curcumin as a Novel Epigenetic Treatment Approach for GFI1-Associated MDS/AML. <i>Experimental Hematology</i> , 2018, 64, S102.	0.2	0
31	Myelodysplastic syndromes and bone loss in mice and men. <i>Leukemia</i> , 2017, 31, 1003-1007.	3.3	25
32	Gfi1b is a novel oncosuppressor, which restricts number of leukemic stem cells. <i>Experimental Hematology</i> , 2017, 53, S90.	0.2	0
33	Growth factor independence 1 (Gfi1) regulates the AML supporting function of mesenchymal stromal cells. <i>Experimental Hematology</i> , 2017, 53, S90.	0.2	2
34	Reduced expression of Gfi1 causes a fatal myeloproliferative disease by simultaneously blocking myeloid differentiation and p53 mediated apoptosis. <i>Experimental Hematology</i> , 2017, 53, S106.	0.2	0
35	Enforced GFI1 expression impedes human and murine leukemic cell growth. <i>Scientific Reports</i> , 2017, 7, 15720.	1.6	13
36	Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. <i>Haematologica</i> , 2016, 101, 1216-1227.	1.7	99

#	ARTICLE	IF	CITATIONS
37	GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome. <i>Experimental Hematology</i> , 2016, 44, 590-595.e1.	0.2	11
38	Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. <i>Experimental Hematology</i> , 2016, 44, 713-726.e14.	0.2	16
39	Low GFI1 expression level drive the development of acute myeloid leukemia and fatal myeloproliferative neoplasia by blocking differentiation and P53-mediated apoptosis. <i>Experimental Hematology</i> , 2016, 44, S71.	0.2	0
40	A 6-Base Pair in Frame Germline Deletion in Exon 7 Of <i>RET</i> Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1016-1022.	1.8	14
41	Virus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8+ T-cell priming and viral control. <i>Scientific Reports</i> , 2016, 6, 19191.	1.6	12
42	High Frequencies of Anti-Host Reactive CD8+ T Cells Ignore Non-Hematopoietic Antigen after Bone Marrow Transplantation in a Murine Model. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 1343-1353.	1.1	5
43	GFI1 as a novel prognostic and therapeutic factor for AML/MDS. <i>Leukemia</i> , 2016, 30, 1237-1245.	3.3	37
44	Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 683-691.	3.3	119
45	GFI1b As a Novel Oncosuppressor in AML. <i>Blood</i> , 2016, 128, 2717-2717.	0.6	4
46	Threshold Levels of Gfi1 Maintain E2A Activity for B Cell Commitment via Repression of Id1. <i>PLoS ONE</i> , 2016, 11, e0160344.	1.1	12
47	the Role of MSCs in the Development of Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2669-2669.	0.6	0
48	From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation. <i>Blood</i> , 2015, 126, 2561-2569.	0.6	89
49	A 6 BP in frame germline deletion in exon 7 of the RET gene leads to increased autophosphorylation, MAPK activation and MEN2. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2015, 122, .	0.6	0
50	A Dominant-Negative <i>GFI1B</i> Mutation in the Gray Platelet Syndrome. <i>New England Journal of Medicine</i> , 2014, 370, 245-253.	13.9	152
51	Gfi1 as a new target and predictive marker in AML. <i>Experimental Hematology</i> , 2014, 42, S20.	0.2	0
52	Gfi136N is a prognostic marker and possible target for the progression of MDS to AML. <i>Experimental Hematology</i> , 2014, 42, S42.	0.2	0
53	Dose Dependent Role of Gfi1 in Human MDS and AML and Its Suitability As a Novel Target. <i>Blood</i> , 2014, 124, 777-777.	0.6	0
54	Functional Inhibition of Mesenchymal Stem and Progenitor Cells (MSPC) Significantly Contributes to Hematopoietic Insufficiency with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3492-3492.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Gfi136N As a Novel Marker and Therapeutic Target of MDS and AML. <i>Blood</i> , 2014, 124, 3245-3245.	0.6	0
56	Function of Growth Factor Independence 1 (GFI1) in the Polarization AML -Associated Stroma. <i>Blood</i> , 2014, 124, 4366-4366.	0.6	0
57	Hand-foot syndrome: common presentation in an uncommon situation. <i>European Journal of Haematology</i> , 2013, 91, 472-472.	1.1	2
58	Growth Factor Independence 1 Antagonizes a p53-Induced DNA Damage Response Pathway in Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2013, 23, 200-214.	7.7	65
59	Gfi1 as a regulator of p53 and a therapeutic target for ALL. <i>Oncotarget</i> , 2013, 4, 374-375.	0.8	9
60	Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2516-2516.	0.6	0
61	A Single Nucleotide Polymorphism Of Growth Factor Independence 1 (GFI136N) is a Novel Prognostic Marker For The Progression Of Myelodysplastic Syndrome To Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2491-2491.	0.6	1
62	Gfi1b-A Novel Tumor Suppressor In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 3795-3795.	0.6	0
63	A Dominant-Negative GFI1B Mutation in Gray Platelet Syndrome. <i>Blood</i> , 2013, 122, LBA-3-LBA-3.	0.6	1
64	Growth Factor Independence 1b (Gfi1b) Regulates The Commitment, Differentiation and Expansion Of Hematopoietic Stem Cells. <i>Blood</i> , 2013, 122, 2433-2433.	0.6	1
65	The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice. <i>Blood</i> , 2012, 120, 4006-4017.	0.6	40
66	GFI1 (growth factor independent 1 transcription repressor). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2012, , .	0.1	0
67	Origin of the brush cell lineage in the mouse intestinal epithelium. <i>Developmental Biology</i> , 2012, 362, 194-218.	0.9	103
68	Growth factor independence 1 (Gfi1) as a regulator of lymphocyte development and activation. <i>Seminars in Immunology</i> , 2011, 23, 368-378.	2.7	55
69	Growth Factor Independence 1 Protects Hematopoietic Stem Cells Against Apoptosis but Also Prevents the Development of a Myeloproliferative-Like Disease. <i>Stem Cells</i> , 2011, 29, 376-385.	1.4	34
70	The Growth Factor Independence 1 variant form GFI136N Predisposes to Acute Myeloid Leukemia by Inducing Epigenetic Changes in Oncogenes Such As Hoxa9. <i>Blood</i> , 2011, 118, 223-223.	0.6	10
71	Growth Factor Independent-1 (Gfi1) As a New Target for Human Leukemia Therapy. <i>Blood</i> , 2011, 118, 560-560.	0.6	0
72	A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. <i>Blood</i> , 2010, 115, 2462-2472.	0.6	46

#	ARTICLE	IF	CITATIONS
73	Evidence that Growth factor independence 1b regulates dormancy and peripheral blood mobilization of hematopoietic stem cells. <i>Blood</i> , 2010, 116, 5149-5161.	0.6	66
74	Zinc Finger Protein Gfi1 Controls the Endotoxin-Mediated Toll-Like Receptor Inflammatory Response by Antagonizing NF- κ B p65. <i>Molecular and Cellular Biology</i> , 2010, 30, 3929-3942.	1.1	28
75	Growth Factor Independence 1 b (Gfi1b) as a New Regulator of Hematopoietic Stem Cell Fate. <i>Blood</i> , 2010, 116, 837-837.	0.6	0
76	Dosage-Sensitive Role of Growth Factor Independence 1 (Gfi1) In the Development of T-Cell Leukemia. <i>Blood</i> , 2010, 116, 706-706.	0.6	0
77	A Human Variant of Growth Factor Independence 1 (GFI136N) Predisposes to Myeloid Leukemia In Mice. <i>Blood</i> , 2010, 116, 997-997.	0.6	1
78	Growth Factor Independent-1 (Gfi1) Is Critically Required for T-Cell Acute Lymphoblastic Leukemia (T-ALL) Tumor Initiation and Maintenance. <i>Blood</i> , 2010, 116, 3156-3156.	0.6	0
79	Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. <i>International Journal of Hematology</i> , 2009, 89, 422-430.	0.7	43
80	Growth Factor Independence 1 (Gfi1) Is Required for Initiation, Maintenance, Progression, and Transplantability of Lymphoma.. <i>Blood</i> , 2009, 114, 447-447.	0.6	0
81	The zinc finger protein Gfi1 is implicated in the regulation of IgG2b production and the expression of $\text{I}\kappa\text{B}\beta$ germline transcripts. <i>European Journal of Immunology</i> , 2008, 38, 3004-3014.	1.6	11
82	The Zinc Finger Protein Gfi1 Controls TLR4-Mediated Inflammatory Response by Directly Antagonizing NF- κ B Transcription Factor. <i>Blood</i> , 2008, 112, 469-469.	0.6	0
83	Growth Factor Independence 1 (Gfi1) Is An Essential Factor for the Development of Lymphoma. <i>Blood</i> , 2008, 112, 297-297.	0.6	0
84	A Variant Allele of the Gene Growth Factor Independence 1 (GFI1) Is Associated with Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 13-13.	0.6	1
85	Loss of Gfi1 Impedes Development of T-Cell Lymphoma upon Exposure to N-ethyl-N-nitrosourea but Predisposes to Severe Myelodysplastic Changes.. <i>Blood</i> , 2007, 110, 2221-2221.	0.6	0
86	Inhibiting PI3K- AKT -mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3